Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broadspectrum protection during Gram-negative bacterial sepsis

Journal of Endotoxin Research

Volumn 4, Issue 2, 1997, Pages 123-153

  Greisman, S E ^a,b   Johnston, C A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; BACTERIUM MUTANT; CONTROLLED STUDY; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HYDROLYSIS; HYPOTHESIS; IMMUNIZATION; MOUSE; NONHUMAN; PROTECTION; REVIEW; SEPSIS;

EID: 0030913250     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1177/096805199700400206     Document Type: Review

References (203)

1. Ledingham J.C.G. Some problems of natural immunity and prophylaxis. The Harben Lectures of 1925. Lecture 1. J State Med 1926; 34: 2-25.
2. Arkwright J.A. The value of different kinds of antigen in prophylactic 'enteric' vaccines. J Pathol Bacteriol 1927; 30: 345-364.
3. Weber R. Weitere experimentelle beiträge zur aktiven immunisierung gegen typhus und cholera [in German]. Z Hyg Infektionskrankheiten (Berlin) 1917; 84: 425-448.
4. Ibraham H.M., Schütze H. A comparison of the prophylactic values of the H, O and R antigens of Salmonella aertrycke, together with some observations on the toxicity of its smooth and rough variants. Br J Exp Pathol 1928; 9: 353-360.
5. De Torregrosa M.V., Francis Jr T. The intracerebral infection of mice with Hemophilus influenzae as an index of strain virulence and the protective value of immune serum. J Infect Dis 1941; 68: 59-66.
6. Kenny K., Herzberg M. Antibody response and protection induced by immunization with smooth and rough strains in experimental salmonellosis. J Bacteriol 1968; 95: 406-417.
7. Holme T., Lindberg A.A., Garegg P.J., Onn T. Chemical composition of cell-wall polysaccharide of rough mutants of Salmonella typhimurium. J Gen Microbiol 1968; 52: 45-54.
8. Blanden R.V., Mackaness G.B., Collins F.M. Mechanisms of acquired resistance in mouse typhoid. J Exp Med 1966; 124: 585-600.
9. Ornellas E.P., Roantree R.J., Steward J.P. The specificity and importance of humoral antibody in the protection of mice against intraperitoneal challenge with complement-sensitive and complement-resistant Salmonella. J Infect Dis 1970; 121: 113-123.
10. Saxen H., Nurrninen M., Kuusi N., Svenson S.B., Mäkelä P.H. Evidence for the importance of O antigen specific antibodies in mouse-protective Salmonella outer membrane protein (porin) antisera. Microb Pathog 1986; 1: 433-441.
11. Chedid L., Parant M., Parant F., Boyer F. A proposed mechanism for natural immunity to enterobacterial pathogens. J Immunol 1968; 100: 292-301.
12. McCabe W.R. Immunization with R mutants of S. minnesota. I. Protection against challenge with heterologous Gram-negative bacilli. J Immunol 1972; 108: 601-610.
13. Ziegler E.J., Douglas H., Sherman J.E., Davis C.E., Braude A.I. Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-GAL epimerase-deficient mutant. J Immunol 1973; 111: 433-438.
14. Ziegler E.J., McCutchan J.A., Douglas H., Braude A.I. Prevention of lethal Pseudomonas bacteremia with epimerase-deficient E. coli antiserum. Trans Assoc Am Physicians 1975; 88: 101-108.
15. Young L.S., Stevens P., Ingram J. Functional role of antibody against 'core' glycolipid of Enterobacteriaceae. J Clin Invest 1975; 56: 850-861.
16. Hodgin L.A., Drews J. Effect of active and passive immunizations with lipid A and Salmonella minnesota Re 595 on Gram-negative infections in mice. Infection 1976; 4: 5-10.
17. Bruins S.C., Stumacher R., Johns M.A., McCabe W.R. Immunization with R mutants of Salmonella minnesota. III. Comparison of the protective effect of immunization with lipid A and the Re mutant. Infect Immun 1977; 17: 16-20.
18. Dunn D.L., Ferguson R.M. Immunotherapy of Gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5. Surgery 1982; 92: 212-219.
19. Konstantinov G., Karacholeva M., Eskenazy M. et al. Passive protection against heterologous Gram-negative bacteria mediated by antiserum to epimeraseless Rc mutant of Salmonella minnesota. Ann Immunol 1982; 133D: 71-76.
20. Marks M.I., Ziegler E.J., Douglas H., Corbeil L.B., Braude A.I. Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide. J Clin Invest 1982; 69: 742-749.
21. Appelmelk B.J., Verwey-van Vught A.M.J.J., Maaskant J.J., Schouten W.F., Thijs L.G., MacLaren D.M. Use of mucin and hemoglobin in experimental murine Gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region. Antonie Van Leeuwenhoek 1986; 52: 537-542.
22. Tate III W.J., Douglas H., Braude A.I., Wells W.W. Protection against lethality of E. coli endotoxin with 'O' antiserum. Ann NY Acad Sci 1966; 133: 746-762.
23. Davis C.E., Brown K.R., Douglas H., Tate III W.J., Braude A.I. Prevention of death from endotoxin with antisera. I. The risk of fatal anaphylaxis to endotoxin. J Immunol 1969; 102: 563-572.
24. Johns M., Skehill A., McCabe W.R. Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin. J Infect Dis 1983; 147: 57-67.
25. Ziegler E.J., McCutchan J.A., Fierer J. et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307: 1225-1230.
26. Baumgartner J-D., Glauser M.P., McCutchan J.A. et al. Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 1985; 2: 59-63.
27. Greisman S.E., Johnston C.A. Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality. J Infect Dis 1988; 157: 54-64.
28. Davis C.E., Ziegler E.J., Arnold K.F. Neutralization of meningococcal endotoxin by antibody to core glycolipid. J Exp Med 1978; 147: 1007-1017.
29. McCabe W.R., De Maria Jr A., Berberich H., Johns M.A. Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. J Infect Dis 1988; 158: 291-300.
30. Braude A.I., Ziegler E.J. Protection against Gram-negative bacteremia with antiserum to endotoxins. In: Nowotny A. Ed. Beneficial Effects of Endotoxins. New York: Plenum, 1983; 111-125.
31. Siber G.R., Kania S.A., Warren H.S. Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other Gram-negative bacteria. J Infect Dis 1985; 152: 954-964.
32. Johns M.A., Bruins S.C., McCabe W.R. Immunization with R mutants of Salmonella minnesota. II. Serological response to lipid A and the lipopolysaccharide of Re mutants. Infect Immun 1977; 17: 9-15.
33. Michael J.G., Mallah I. Immune response to parental and rough mutant strains of Salmonella minnesota. Infect Immun 1981; 33: 784-787.
34. Schlecht S., Böhlck I., Westphal O. Nachweis von Antikörpern gegen Salmonella-R-Antigene in Salmonella-O-Antiseren. Zentralbl Bakteriol Orig A 1971; 216: 472-482.
35. Greisman S.E., DuBuy J.B., Woodward C.L. Experimental Gram-negative bacterial sepsis: reevaluation of the ability of rough mutant antisera to protect mice. Proc Soc Exp Biol Med 1978; 158: 482-490.
36. Greisman S.E., DuBuy J.B., Woodward C.L. Experimental Gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone. Infect Immun 1979; 25: 538-557.
37. Ng A-K., Chen C-L.H., Chang C-M., Nowotny A. Relationship of structure to function in bacterial endotoxins: serologically cross-reactive components and their effect on protection of mice against some Gram-negative infections. J Gen Microbiol 1976; 94: 107-116.
38. Peter G., Chernow M., Keating M.H., Ryff J.C., Zinner S.H. Limited protective effect of rough mutant antisera in murine Escherichia coli bacteremia. Infection 1982; 10: 228-232.
39. van Dijk W.C., Verbrugh H.A., van Erne-van der Tol M.E., Peters R., Verhoef J. Escherichia coli antibodies in opsonisation and protection against infection. J Med Microbiol 1981; 14: 381-389.
40. Trautmann M., Hahn H. Antiserum against Escherichia coli J5: a re-evaluation of its in vitro and in vivo activity against heterologous Gram-negative bacteria. Infection 1985; 13: 140-145.
41. Vuopio-Varkila J. Experimental Escherichia coli peritonitis in immunosuppressed mice: the role of specific and non-specific immunity. J Med Microbiol 1987; 24: 33-39.
42. Vuopio-Varkila J., Karvonen M., Saxen H. Protective capacity of antibodies to outer-membrane components of Escherichia coli in a systemic mouse peritonitis model. J Med Microbiol 1988; 25: 77-84.
43. Baumgartner J.D., Heumann D., Gerain J., Weinbreck P., Grau G.E., Glauser M.P. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor α and interleukin 6. J Exp Med 1990; 171: 889-896.
44. Welch W.D., Martin W.J., Stevens P., Young L.S. Relative opsonic and protective activities of antibodies against K1, O and lipid A antigens of Escherichia coli. Scand J Infect Dis 1979; 11: 291-301.
45. Wickstrom M.I., Gay C.C., Hodgson J.L. et al. Cross-reactive antibody in immunity to colisepticemia in calves. Vet Microbiol 1987; 13: 259-271.
46. Morris D.D., Whitlock R.H. Therapy of suspected septicemia in neonatal foals using plasma-containing antibodies to core lipopolysaccharide (LPS). J Vet Intern Med 1987; 1: 175-182.
47. Selim S.A., Holmberg C.A., Cullor J.S. Passive immunotherapy in neonatal calves. II. The efficacy of a J5 Escherichia coli hyperimmune plasma as immunotherapy in neonatal calves. Vaccine 1995; 13: 1454-1459.
48. Cryz Jr S.J., Meadow P.M., Furer E., Germanier R. Protection against fatal Pseudomonas aeruginosa sepsis by immunization with smooth and rough lipopolysaccharides. Eur J Clin Microbiol Infect Dis 1985; 4: 180-185.
49. Sadoff J.C., Futrovsky S.L., Sidberry H.F., Iglewski B.H., Seid Jr R.C. Detoxified lipopolysaccharide-protein conjugates. Semin Infect Dis 1982; 4: 346-354.
50. Sakulramrung R., Domingue G.J. Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5. J Infect Dis 1985; 151: 995-1004.
51. Pennington J.E., Hickey W.F., Blackwood L.L., Arnaut M.A. Active immunization with lipopolysaccharide pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs. J Clin Invest 1981; 68: 1140-1148.
52. Pennington J.E., Menkes E. Type-specific vs. cross-protective vaccination for Gram-negative bacterial pneumonia. J Infect Dis 1981; 144: 599-603.
53. Greisman S.E., Young E.J., DuBuy B. Mechanisms of endotoxin tolerance. VIII. Specificity of serum transfer. J Immunol 1973; 111: 1349-1360.
54. Milner K.C. Patterns of tolerance to endotoxin. J Infect Dis 1973; 128 (Suppl): S237-S245.
55. Ralovich B., Emödy L., Lang C. Problems of antiendotoxic immunity. J Hyg Epidemiol Microbiol Immunol 1974; 18: 439-446.
56. Morris D.D., Cullor J.S., Whitlock R.H., Wickstrom M., Corbeil L.B. Endotoxemia in neonatal calves given antiserum to a mutant Escherichia coli (J-5). Am J Vet Res 1986; 47: 2554-2565.
57. Morris D.D., Whitlock R.H., Corbeil L.B. Endotoxemia in horses: protection provided by antiserum to core lipopolysaccharide. Am J Vet Res 1986; 47: 544-550.
58. Girotti M.J., Menkes E., MacDonald J.W.D., Hong K., Patterson A., Todd T.R.J. Effects of immunization on cardiopulmonary alterations of Gram-negative endotoxemia. J Appl Physiol 1984; 56: 582-589.
59. Miner K.M., Manyak C.L., Williams E. et al. Characterization of murine monoclonal antibodies to Escherichia coli J5. Infect Immun 1986; 52: 56-62.
60. de Jongh-Leuvenink J., Vreede R.W., Marcelis J.H., de Vos M., Verhoef J. Detection of antibodies against lipopolysaccharides of Escherichia coli and Salmonella R and S strains by immunoblotting. Infect Immun 1985; 50: 716-720.
61. Mehta N.D., Wilson B.M., Rapson N.T., Easmon C.S.F., Comparison of the opsonic activity of polyclonal and monoclonal antibodies raised against Salmonella Minnesota strain R595 J Med Microbiol 1988; 25: 85-93.
62. DeMaria Jr A., Johns M.A., Berberich H., McCabe W.R. Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects. J Infect Dis 1988; 158: 301-311.
63. Cross A.S., Sidberry H., Sadoff J.C. The human antibody response during natural bacteremic infection with Gram-negative bacilli against lipopolysaccharide core determinants. J Infect Dis 1989; 160: 225-236.
64. Heumann D., Baumgartner J.D., Jacot-Guillarmod H., Glauser M.P. Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharides. J Infect Dis 1991; 163: 762-768.
65. Baumgartner J.D., Heumann D., Calandra T., Glauser M.P. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5. J Infect Dis 1991; 163: 769-772.
66. Ng A.K., Chang C.M., Chen C.H., Nowotny A. Comparison of the chemical structure and biological activities of the glycolipids of Salmonella minnesota R595 and Salmonella typhimurium SI.1102. Infect Immun 1974; 10: 938-947.
67. Dlabac V. The sensitivity of smooth and rough mutants of Salmonella typhimurium to bactericidal and bacteriolytic action of serum, lysozyme and to phagocytosis. Folia Microbiol 1968; 13: 439-449.
68. Schiller N.L. Characterization of the susceptibility of Pseudomonas aeruginosa to complement-mediated killing: role of antibodies to the rough lipopolysaccharide on serum-sensitive strains. Infect Immun 1988; 56: 632-639.
69. Schmidt G., Jann B., Jann K. Immunochemistry of R lipopolysaccharides of Escherichia coli: studies on R mutants with an incomplete core, derived from E. coli O8: K27. Eur J Biochem 1970; 16: 382-392.
70. Lyman M.B., Steward J.P., Roantree R.J. Characterization of the virulence and antigenic structure of Salmonella typhimurium strains with lipopolysaccharide core defects. Infect Immun 1976; 13: 1539-1542.
71. Lind S.M., Carlin N.I.A., Lindberg A.A. Production and characterisation of KDO-specific monoclonal antibodies recognizing lipopolysaccharides from heptoseless mutants of Salmonella. FEMS Microbiol Lett 1985; 28: 45-49.
72. Appelmelk B.J., Verweij-van Vught A.M.J.J., Maaskant J.J. et al. Production and characterization of mouse monoclonal antibodies reacting with the lipopolysaccharide core region of Gram-negative bacilli. J Med Microbiol 1988; 26: 107-114.
73. Pollack M., Chia J.K.S., Koles N.L., Miller M., Guelde G. Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide. J Infect Dis 1989; 159: 168-188.
74. Brade L., Kosma P., Appelmelk B.J., Paulsen H., Brade H. Use of synthetic antigens to determine the epitope specificities of monoclonal antibodies against the 3-deoxy-D-mannooctulosonate region of bacterial lipopolysaccharide. Infect Immun 1987; 55: 462-466.
75. Rozalski A., Brade L., Kosma P., Appelmelk B.J., Krogmann C., Brade H. Epitope specificities of murine monoclonal and rabbit polyclonal antibodies against enterobacterial lipopolysaccharides of the Re chemotype. Infect Immun 1989; 57: 2645-2652.
76. Nnalue N.A., Lind S.M., Lindberg A.A. The disaccharide L-α-D-heptose 1→7-L-α-D-heptose 1 → of the inner core domain of Salmonella lipopolysaccharide is accessible to antibody and is the epitope of a broadly reactive monoclonal antibody. J Immunol 1992; 149: 2722-2728.
77. Di Padova F.E., Brade H., Barclay G.R. et al. A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immun 1993; 61: 3863-3872.
78. Di Padova F.E., Mikol V., Barclay G.R., Poxton I.R., Brade H., Rietschel E.T. Anti-lipopolysaccharide core antibodies. In: Levin J., van Deventer S.J.H., van der Poll T., Struk A. Eds. Bacterial Endotoxins. New York: Wiley-Liss, 1994; 85-94.
79. Schwartzer T.A., Alcid D.V., Numsuwan V., Gocke D.J. Immunochemical specificity of human antibodies to lipopolysaccharide from the J5 rough mutant of Escherichia coli O111: B4. J Infect Dis 1989; 159: 35-42.
80. Appelmelk B.J., Verweij-van Vught A.M.J.J., Maaskant J.J., Thijs L.G., MacLaren D.M. Cross-reactivity of antibodies to lipopolysaccharides from Escherichia coli J5. J Infect Dis 1986; 154: 538.
81. Siber G.R. Reply. J Infect Dis 1986; 154: 539.
82. Baumgartner J.D., O'Brien T.X., Kirkland T.N., Glauser M.P., Ziegler E.J. Demonstration of cross-reactive antibodies to smooth Gram-negative bacteria in antiserum to Escherichia coli J5. J Infect Dis 1987; 156: 136-143.
83. Nelles MJ, Niswander C.A. Mouse monoclonal antibodies reactive with J5 lipopolysaccharide exhibit extensive serological cross-reactivity with a variety of Gram-negative bacteria. Infect Immun 1984; 46: 677-681.
84. Kirkland T.N., Colwell D.E., Michalek S.M., McGhee J.R., Ziegler E.J. Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies. J Immunol 1986; 137: 3614-3619.
85. Pollack M., Raubitschek A.A., Larrick J.W. Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides. J Clin Invest 1987; 79: 1421-1430.
86. Bogard Jr W.C., Dunn D.L., Abernethy K., Kilgarriff C., Kung P.C. Isolation and characterization of murine monoclonal antibodies specific for Gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity. Infect Immun 1987; 55: 899-908.
87. Dunn D.L., Ewald D.C., Chandan N., Cerra F.B. Immunotherapy of Gram-negative bacterial sepsis: a single murine monoclonal antibody provides cross-genera protection. Arch Surg 1986; 121: 58-62.
88. Dunn D.L., Bogard Jr W.C., Cerra F.B. Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis. Surgery 1985; 98: 283-289.
89. Gigliotti F., Shenep J.I. Failure of monoclonal antibodies to core glycolipid to bind intact smooth strains of Escherichia coli. J Infect Dis 1985; 151: 1005-1011.
90. Shenep J.L., Gigliotti F., Davis D.S., Hildner W.K. Reactivity of antibodies to core glycolipid with Gram-negative bacteria. Rev Infect Dis 1987; 9 (Suppl 5): S639-S643.
91. Peters H., Jürs M., Jann B., Jann K., Timmis K.M., Bitter-Suermann D. Monoclonal antibodies to enterobacterial common antigen and to Escherichia coli lipopolysaccharide outer core: demonstration of an antigenic determinant shared by enterobacterial common antigen and E. coli K5 capsular polysaccharide. Infect Immun 1985; 50: 459-466.
92. Tsang R.S.W., Chan K.H., Chau P.Y., Wan K.C., Ng M.H., Schlecht S. A murine monoclonal antibody specific for the outer core oligosaccharide of Salmonella lipopolysaccharide. Infect Immun 1987; 55: 211-216.
93. Aydintug M.K., Inzana T.J., Letonja T., Davis W.C., Corbeil LB. Cross-reactivity of monoclonal antibodies to Escherichia coli J5 with heterologous Gram-negative bacteria and extracted lipopolysaccharides. J Infect Dis 1989; 160: 846-857.
94. Crowley J.P., Zinner S.H., Peter G. Opsonization of serum-sensitive and serum-resistant Escherichia coli by rough mutant (Re) antisera. J Lab Clin Med 1982; 99: 197-205.
95. Helving T.B., Grewal K.K., Oberwalder U., Hammerschmid F., Jaksche H. Prospects for the development of a hyperimmunoglobulin with activity against Gram-negative organisms. In: Nydegger U.E. Ed. Immunothemotherapy: A Guide to Immunoglobulin Prophylaxis and Therapy. New York: Academic Press, 1981; 141-150.
96. Overbeek B.P., Schellekens J.F.P., Lippe W., Dekker B.A.T., Verhoef J. Carumonam enhances reactivity of Escherichia coli with mono- and polyclonal antisera to rough mutant Escherichia coli J5. J Clin Microbiol 1987; 25: 1009-1013.
97. Vreede R.W., Marcelis J.H., Verhoef J. Antibodies raised against rough mutants of Escherichia coli and Salmonella strains are opsonic only in the presence of complement. Infect Immun 1986; 52: 892-896.
98. Tsuchido T., Katsui N., Takeuchi A., Takano M., Shibasaki I. Destruction of the outer membrane permeability barrier of Escherichia coli by heat treatment. Appl Environ Microbiol 1985; 50: 298-303.
99. Porat R., Johns M.A., McCabe W.R. Selective pressures and lipopolysaccharide subunits as determinants of resistance of clinical isolates of Gram-negative bacilli to human serum. Infect Immun 1987; 55: 320-328.
100. Joiner K.A., Hammer C.H., Brown E.J., Cole R.J., Frank M.M. Studies on the mechanism of bacterial resistance to complement-mediated killing. 1. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death. J Exp Med 1982; 155: 797-808.
101. Joiner K.A., Hammer C.H., Brown E.J., Frank M.M. Studies on the mechanism of bacterial resistance to complement-mediated killing II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane. J Exp Med 1982; 155: 809-819.
102. Grossman N., Schmetz M.A., Foulds J. et al. Lipopolysaccharide size and distribution determine serum resistance in Salmonella montevideo. J Bacteriol 1987; 169: 856-863.
103. Ihara I., Ihara S., Nagashima A., Ji Y-H., Kawakami M. The 28k and 70k dalton polypeptide components of mouse Ra-reactive factor are responsible for bactericidal activity. Biochem Biophys Res Commun 1988; 152: 636-641.
104. Freudenberg M.A., Galanos C. Alterations in rats in vivo of the chemical structure of lipopolysaccharide from Salmonella abortus equi. Eur J Biochem 1985; 152: 353-359.
105. Freudenberg M.A., Kleine B., Galanos C. The fate of lipopolysaccharide in rats: evidence for chemical alteration in the molecule. Rev Infect Dis 1984; 6: 483-487.
106. McCallus D.E., Norcross N.L. Antibody specific for Escherichia coli J5 cross-reacts to various degrees with an Escherichia coli clinical isolate grown for different lengths of time. Infect Immun 1987; 55: 1042-1046.
107. Tesh V.L., Morrison D.C. The physical-chemical characterization and biologic activity of serum released lipopolysaccharides. J Immunol 1988; 141: 3523-3531.
108. Kelly N.M., Bell A., Hancock R.E.W. Surface characteristics of Pseudomonas aeruginosa grown in a chamber implant model in mice and rats. Infect Immun 1989; 57: 344-350.
109. Sadoff J.C., Wright D.C., Futrovsky S., Sidberry H., Collins H., Kaufmann B. Characterization of mouse monoclonal antibodies directed against Pseudomonas aeruginosa lipopolysaccharides. Antibiot Chemother 1985; 36: 134-146.
110. Young L.S. Monoclonal antibodies: technology and application to Gram-negative infections. Infection 1985; 13 (Suppl 2): S224-S228.
111. Johnston C.A., Greisman S.E. Endotoxemia induced by antibiotic therapy: a mechanism for adrenal corticosteroid protection in Gram-negative sepsis. Trans Assoc Am Physicians 1984; 97: 172-181.
112. Flynn P.M., Shenep J.L., Gigliotti F., Davis D.S., Hildner W.K. Immunolabeling of lipopolysaccharide liberated from antibiotic-treated Escherichia coli. Infect Immun 1988; 56 : 2760-2762.
113. Cross A.S., Gemski P., Sadoff J.C., Ørskov F., Ørskov I. The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis 1984; 149: 184-193.
114. Weyand C., Goronzy J., Fathman C.G., O'Hanley P. Administration in vivo of recombinant interleukin 2 protects mice against septic death. J Clin Invest 1987; 79: 1756-1763.
115. Young L.S., Stevens P. Cross-protective immunity to Gram-negative bacilli: studies with core glycolipid of Salmonella minnesota and antigens of Streptococcus pneumoniae. J Infect Dis 1977; 136 (Suppl): S174-S180.
116. Izui S., Eisenberg R.A., Dixon F.J. Subclass-restricted IgG polyclonal antibody production in mice injected with lipid A-rich lipopolysaccharides. J Exp Med 1981; 153: 324-338.
117. Martinez D., Callahan III L.T. Prophylaxis of Pseudomonas aeruginosa infections in leukopenic mice by a combination of active and passive immunization. Eur J Clin Microbiol Infect Dis 1985; 4: 186-189.
118. Ahlstedt S. Experimental Escherichia coli O6 infection in mice. II. Protective factors of immunity after immunosuppression. Scand J Infect Dis [Suppl] 1980; 24: 216-219.
119. Zweerink H.J., Gammon M.C., Hutchison C.F. et al. X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa. Infect Immun 1988; 56: 1209-1214.
120. Zweerink H.J., Gammon M.C., Hutchison C.F. et al. Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa. Infect Immun 1988; 56: 1873-1879.
121. Ziegler E.J. Protective antibody to endotoxin core: the emperor's new clothes? J Infect Dis 1988; 158: 286-290.
122. Raskova H. Nonspecific endotoxin-like resistance induced by simple chemical compounds. In: Landy M., Braun W. Eds. Bacterial Endotoxins. New Brunswick, NJ: The Institute of Microbiology at Rutgers, 1964; 546-561.
123. Kindmark C.O. Stimulating effect of C-reactive protein on phagocytosis of various species of pathogenic bacteria. Clin Exp Immunol 1971; 8: 941-948.
124. 2 macroglobulin of the rat, an acute phase protein, mitigates the early course of endotoxin shock. Br J Exp Pathol 1986; 67: 313-319.
125. Warren H.S., Knights C.V., Siber G.R. Neutralization and lipoprotein binding of lipopolysaccharides in tolerant rabbit serum. J Infect Dis 1986; 154: 784-791.
126. Warren H.S., Novitsky T.J., Bucklin A., Kania S.A., Siber G.R. Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other Gram-negative bacteria. Infect Immun 1987; 55: 1668-1673.
127. Warren H.S., Novitsky T.J., Ketchum P.A., Roslansky P.F., Kania S., Siber G.R. Neutralization of bacterial lipopolysaccharides by human plasma. J Clin Microbiol 1985; 22: 590-595.
128. Warren H.S., Novitsky T.J., Martin P., Roslansky P.F., Siber G.R. Endotoxin neutralizing capacity of sera from different patient populations assessed by the Limulus lysate test. Prog Clin Biol Res 1987; 231: 341-348.
129. Riveau G.R., Novitsky T.J., Roslansky P.F., Dinarello C.A., Warren H.S. Role of interleukin-1 in augmenting serum neutralization of bacterial lipopolysaccharide. J Clin Microbiol 1987; 25: 889-892.
130. Warren H.S., Riveau G.R., de Deckker F.A., Chedid L.A. Control of endotoxin activity and interleukin-1 production through regulation of lipopolysaccharide-lipoprotein binding by a macrophage factor. Infect Immun 1988; 56: 204-212.
131. Wurfel M.M., Kunitake S.T., Lichenstein H., Kane J.P., Wright S.D. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180: 1025-1035.
132. Gallay P., Heumann D., Le Roy D., Barras C., Glauser M.P. Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock. Proc Natl Acad Sci USA 1993; 90: 9935-9938.
133. Gallay P., Heumann D., Le Roy D., Barras C., Glauser M.P. Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc Natl Acad Sci USA 1994; 91: 7922-7926.
134. Alcorn J.M., Fierer J., Chojkier M. The acute-phase response protects mice from D-galactosamine sensitization to endotoxin and tumor necrosis factor-α. Hepatology 1992; 15: 122-129.
135. Vogels M.T.E., Cantoni L., Carelli M., Sironi M., Ghezzi P., van der Meer J.W.M. Role of acute-phase proteins in interleukin-1-induced nonspecific resistance to bacterial infections in mice. Antimicrob Agents Chemother 1993; 37: 2527-2533.
136. van der Meer J.W.M., Helle M., Aarden L. Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 on nonspecific resistance to infection. Eur J Immunol 1989; 19: 413-416.
137. Barton B.E., Jackson J.V. Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 1993; 61: 1496-1499.
138. Bucklin S.E., Silverstein R., Morrison D.C. An interleukin-6 induced acute-phase response does not confer protection against lipopolysaccharide lethality. Infect Immun 1993; 61: 3184-3189.
139. Kopf M., Baumann H., Freer G. et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339-342.
140. Bluethmann H., Rothe J., Schultze N., Tkachuk M., Koebel P. Establishment of the role of IL-6 and TNF receptor 1 using gene knockout mice. J Leukoc Biol 1994; 56: 565-570.
141. Ozaki Y., Ohashi T., Minami A., Nakamura S. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1α. Infect Immun 1987; 55: 1436-1440.
142. van der Meer J.W.M., Barza M., Wolff S.M., Dinarello C.A. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal Gram-negative infection. Proc Natl Acad Sci USA 1988; 85: 1620-1623.
143. Morikage T., Mizushima Y., Sakamoto K., Yano S. Prevention of fatal infections by recombinant human interleukin 1α in normal and anticancer drug-treated mice. Cancer Res 1990; 50: 2099-2104.
144. Koj A. Acute phase reactants. Their synthesis, turnover and biological significance. In: Allison AC. Ed. Structure and Function of Plasma Proteins, vol 1. New York: Plenum, 1974; 73-131.
145. Darcy D.A. Enhanced response of an 'acute phase' serum protein to repeated tissue damage in the rat. Br J Exp Pathol 1966; 47: 480-487.
146. Weimer H.E., Humelbaugh C. The effects of-periodic challenge on the response of α2-AP globulin and other acute-phase reactants of rat serum to tissue injury. Can J Physiol Pharmacol 1967; 45: 241-247.
147. Baumann H., Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
148. 51Cr-labeled somatic antigens of smooth and rough Salmonellae. Ann NY Acad Sci 1966; 133: 712-726.
149. Freudenberg M.A., Galanos C. The metabolic fate of endotoxins. Prog Clin Biol Res 1988; 272: 63-75.
150. Baumann H., Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990; 7: 147-159.
151. Hill M.R., McKinney K.L., Marks M.I., Hyde R.M. Comparative analysis of Haemophilus influenzae type b and Escherichia coli J5 lipopolysaccharides. J Med Microbiol 1986; 21: 25-33.
152. Parant M., Boyer F., Chedid L. Augmentation de la resistance aux infections consecutive a une injection d'endotoxine. Mise en evidence du mecanisme par l'association de sulfamide. CR Acad Sci III 1965; 260: 2630-2633.
153. Nys M., Cloes J.M., Demonty J., Joassin L. Protective effects of polyclonal sera and of monoclonal antibodies active to Salmonella minnesota Re595 lipopolysaccharide during experimental endotoxemia. J Infect Dis 1990; 162: 1087-1095.
154. Bhattacharjee A.K., Opal S.M., Palardy J.E. et al. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against Gram-negative bacterial sepsis. J Infect Dis 1994; 170: 622-629.
155. Bhattacharjee A.K., Opal S.M., Taylor R. et al. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria mettingitidis group B outer membrane protein produces protective antibodies against Gram-negative bacteremia. J Infect Dis 1996; 173: 1157-1163.
156. Jennings H.J., Lugowski C., Ashton F.E. Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis. Infect Immun 1984; 43: 407-412.
157. Schneider H., Hale T.L., Zollinger W.D., Seid Jr R.C., Hammack C.A., Griffiss J.M. Heterogeneity of molecular size and antigenic expression within lipooligosaccharides of individual strains of Neisseria gonorrhoeae and Neisseria meningitidis. Infect Immun 1984; 45: 544-549.
158. Griffiss J.M., Schneider H., Mandrell R.E. et al. The immunochemistry of neisserial LOS. Antonie Van Leewenhoek 1987; 53: 501-507.
159. Teng N.N.H., Kaplan H.S., Hebert J.M. et al. Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 1985; 82: 1790-1794.
160. Lugowski C., Romanowska E. Biological properties of lipid A from Shigella sonnei. Eur J Biochem 1974; 48: 81-87.
161. Mattsby-Baltzer I., Kaijser B. Lipid A and anti-lipid A. Infect Immun 1979; 23: 758-763.
162. Mullan N.A., Newsome P.M., Cunnington P.G., Palmer G.H., Wilson M.E. Protection against Gram-negative infections with antiserum to lipid A from Salmonella minnesota R595. Infect Immun 1974; 10: 1195-1201.
163. Elkins K., Metcalf E.S. Binding activity of a murine anti-lipid A monoclonal antibody. Infect Immun 1985; 48: 597-600.
164. Galanos C., Lüderitz O., Westphal O. Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. Eur J Biochem 1971; 24: 116-122.
165. Galanos C., Freudenberg M.A., Jay F. et al. Immunogenic properties of lipid A. Rev Infect Dis 1984; 6: 546-552.
166. Brade H., Galanos C. Common lipopolysaccharide specificity: new type of antigen residing in the inner core region of S- and R-form lipopolysaccharides from different families of Gram-negative bacteria. Infect Immun 1983; 42: 250-256.
167. Kirkland T.N., Ziegler E.J., Tobias P. et al. Inhibition of lipopolysaccharide activation of 70Z/3 cells by anti-lipopolysaccharide antibodies. J Immunol 1988; 141: 3208-3213.
168. Warren H.S., Amato S.F., Fitting C. et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 1993; 177: 89-97.
169. Rietschel E.T., Brade L., Holst O. et al. Molecular structure of bacterial endotoxin in relation to bioactivity. In: Nowotny A., Spitzer J.J., Ziegler E.J. Endotoxin Research Series, Vol 1, Cellular and Molecular Aspects of Endotoxin Reactions. Amsterdam: Elsevier, 1990; 15-32.
170. Rietschel E.T., Galanos C. Lipid A antiserum-mediated protection against lipopolysaccharide- and lipid A-induced fever and skin necrosis. Infect Immun 1977; 15: 34-49.
171. Salles M.F., Mandine E., Zalisz R., Guenounou M., Smets P. Protective
172. Johnston C.A., Greisman S.E. Mechanisms of endotoxin tolerance. In: Hinshaw L.B. Ed. Handbook of Endotoxin. Vol 2: Pathophysiology of Endotoxin. Amsterdam: Elsevier, 1985; 359-401.
173. Rowley D. Endotoxin-induced changes in susceptibility to infections. In: Landy M., Braun W. Eds. Bacterial Endotoxins. New Brunswick, NJ: Institute of Microbiology at Rutgers, 1964; 359-372.
174. Chong K-T., Huston M. Implications of endotoxin contamination in the evaluation of antibodies to lipopolysaccharides in a murine model of Gram-negative sepsis. J Infect Dis 1987; 156: 713-719.
175. Woods J.P., Black J.R., Barritt D.S., Connell T.D., Cannon J.G. Resistance to meningococcemia apparently conferred by anti-H.8 monoclonal antibody is due to contaminating endotoxin and not to specific immunoprotection. Infect Immun 1987; 55: 1927-1928.
176. Fang I.S., Wisniewski M.A., Huntenburg C.C., Knight L.S., Bubbers J.E., Schneidkraut M.J. Inhibition of lipopolysaccharide-associated endotoxin activities in vitro and in vivo by the human anti-lipid A monoclonal antibody SdJ5-1.17.15. Infect Immun 1993; 61: 3873-3878.
177. Appelmelk B.J., Verweij-van Vught M., Brade H. et al. Production, characterization and biological effects of monoclonal antibodies to different parts of the Gram-negative lipopolysaccharide core region. Prog Clin Biol Res 1988; 272: 373-382.
178. Dunn D.L., Priest B.P., Condie R.M. Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. Arch Surg 1988; 123: 1389-1393.
179. Landy M., Pillemer L. Increased resistance to infection and accompanying alteration in properdin levels following administration of bacterial lipopolysaccharides. J Exp Med 1956; 104: 383-409.
180. Freudenberg M.A., Galanos C. Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immun 1988; 56: 1352-1357.
181. Greisman S.E., Young E.J., Workman J.B., Ollodart R.M., Hornick R.B. Mechanisms of endotoxin tolerance: the role of the spleen. J Clin Invest 1975; 56: 1597-1607.
182. Michael J.G., Whitby J.L., Landy M. Studies on natural antibodies to Gram-negative bacteria. J Exp Med 1962; 115: 131-146.
183. Gaines S., Landy M. Prevalence of antibody to Pseudomonas in normal human sera. J Bacteriol 1955; 69: 628-633.
184. Pollack M., Young L.S. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest 1979; 63: 276-286.
185. Gaffin S.L. Gram-negative bacteraemia: new therapeutic possibilities with anti-endotoxin antibodies. Haematol Blood Transfus 1985; 29: 107-111.
186. Heidelberger M., Horton D., Haskell T.H. Cross-reactions of lipopolysaccharides of Pseudomonas aeruginosa in antipneumococcal and other antisera. Infect Immun 1986; 54: 928-930.
187. Pavlovskis O.R., Pollack M., Callahan III L.T., Iglewski B.H. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections. Infect Immun 1977; 18: 596-602.
188. Pavlovskis O.R., Edman D.C., Leppla S.H., Wretlind B., Lewis L.R., Martin K.E. Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids. Infect Immun 1981; 32: 681-689.
189. Cross A.S., Sadoff J.C., Iglewski B.H., Sokol P.A. Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans. J Infect Dis 1980; 142: 538-546.
190. Cross A.S., Zollinger W., Mandrell R., Gemski P., Sadoff J. Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli. J Infect Dis 1983; 147: 68-76.
191. Kim K.S., Cross A.S., Zollinger W., Sadoff J. Prevention and therapy of experimental Eschierichia coli infection with monoclonal antibody. Infect Immun 1985; 50: 734-737.
192. Bortolussi R., Ferrieri P. Protection against Escherichia coli K1 infection in newborn rats by antibody to K1 capsular polysaccharide antigen. Infect Immun 1980; 28: 111-117.
193. Zinner S.H., McCabe W.R. Effects of IgM and IgG antibody in patients with bacteremia due to Gram-negative bacilli. J Infect Dis 1976; 133: 37-45.
194. McCabe W.R., Kaijser B., Olling S., Uwaydah M., Hanson LA. Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates. J Infect Dis 1978; 138: 33-41.
195. Ørskov F., Ørskov I. Escherichia coli O: H serotypes isolated from human blood. Prevalence of the K1 antigen with technical details of O and H antigenic determination. Acta Pathol Microbiol Immunol Scand [B] 1975; 83: 595-600.
196. Kreger B.E., Craven D.E., Carling P.C., McCabe W.R. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980; 68: 332-355.
197. Young L.S., Stevens P., Kaijser B. Gram-negative pathogens in septicaemic infections. Scand J Infect Dis [Suppl] 1982; 31: 78-94.
198. Warren H.S., Chedid L.A. Strategies for the treatment of endotoxemia: significance of the acute-phase response. Rev Infect Dis 1987; 9: S630-S638.
199. McCutchan J.A., Wolf J.L., Ziegler E.J., Braude A.I. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, Gram-negative infections in patients with prolonged neutropenia. Schweiz Med Wochenschr 1983; 113 (Suppl 14): 40-45.
200. Lecomte F., Tilly H., Grise G. et al. Traitement preventif des infections a bacille a gram negatif par des anticorps antilipopolysaccharides. Presse Med 1989; 18: 1419-1422.
201. Calandra T., Glauser M.P., Schellekens J., Verhoef J., the Swiss-Dutch J5 Immunoglobulin Study Group. Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis 1988; 158: 312-319.
202. The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992; 327: 234-240.
203. J5 Study Group. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J Infect Dis 1992; 165: 695-701.